Buscar
Adlai Nortye Ltd
ANLAñadir a la lista de seguimiento
15.570USD
-0.170-1.08%
Cierre 09-18 16:00（ET）
743.45MCap. mercado
PérdidaP/E TTM
Más Datos de Adlai Nortye Ltd Compañía
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
Perfil de Adlai Nortye Ltd
Símbolo de cotizaciónANL
Nombre de la empresaAdlai Nortye Ltd
Fecha de salida a bolsaSep 29, 2023
Director ejecutivoBirgerson (Lars Erik)
Número de empleados123
Tipo de seguridadDepository Receipt
Fin del año fiscalSep 29
Direcciónc/o PO Box 309
CiudadGRAND CAYMAN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCayman Islands
Código postalKY1-1104
Teléfono18482307430
Sitio Webhttps://www.adlainortye.com/
Símbolo de cotizaciónANL
Fecha de salida a bolsaSep 29, 2023
Director ejecutivoBirgerson (Lars Erik)
Ejecutivos de Adlai Nortye Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
136.67K
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
136.67K
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
136.67K
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
136.67K
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
99.99K
-0.01%
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
99.99K
-0.01%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
166.67K
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
136.67K
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
136.67K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Adlai Nortye Ltd?
Los cinco principales accionistas de Adlai Nortye Ltd son: Mr. Lars Erik Birgerson
¿Cuántas instituciones poseen acciones de Adlai Nortye Ltd (ANL)?
A fecha de 2026Q1, 13 instituciones poseen acciones de Adlai Nortye Ltd, con un valor de mercado combinado de aproximadamente 3.40M, lo que representa el 7.18% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 3307188.00.